Ramy Ibrahim

Clinical Development Leader in Immuno-Oncology and Cell Therapy

San Francisco, California, United States

Summary

Ramy Ibrahim is a highly experienced leader in clinical development for cancer immunotherapy, with over two decades of drug development experience across various roles in pharmaceutical companies and non-profit organizations. He has held significant leadership positions such as Chief Medical Officer at the Parker Institute for Cancer Immunotherapy and bit.bio, and is currently the Chief Medical and Strategy Officer at Georgiamune Inc. georgiamune+3

He played a pivotal role in the development of several breakthrough immune checkpoint inhibitor therapies, including ipilimumab (Yervoy®), nivolumab (Opdivo®), durvalumab (Imfinzi®), and tremelimumab during his tenures at Bristol-Myers Squibb and AstraZeneca. globenewswire+2

Ramy Ibrahim has a strong background in academic research and medical oncology, having trained at the National Cancer Institute in Bethesda, MD, where he conducted bench and clinical immunotherapy research, and completed his medical oncology fellowship at the National Cancer Institute, Cairo University. globenewswire+2

He is actively involved in the broader cancer immunotherapy community, serving on the boards of various organizations like the Parker Institute for Cancer Immunotherapy, Cancer Help Desk, Surface Oncology Inc., 2seventy bio, and bluebird bio. He is also a co-author on scientific publications related to advancements in immunotherapy. bit+4

Work

Education

Writing

Approaches to overcome the current treatment plateau in immunotherapy

January 1, 2025

Discusses lessons from current immunotherapies and proposes avenues to overcome the current plateau of cancer immunotherapy, including immune checkpoint inhibitors. Ramy Ibrahim is listed as an author.